Inventiva

IVA

Capitalización de mercado USD 695 M

Inventiva receives a speculative strong buy rating, with a probability-weighted fair value of ~$15 per share versus ~$3.20 currently. Following strong Phase 2b NATIVE results, lanifibranor's pivotal Phase 3 NATiV3 readout is imminent, creating a major potential catalyst for the stock. The model yields a 40% probability of a $29 fair value per share, versus a 32% probability of near-total loss, with intermediate valuations reflecting varying degrees of clinical differentiation.

Small-cap stocks tend to fly under the radar. Often in startup stages, these companies can lack analyst coverage, be overlooked by institutional investors, and be illiquid due to low average trading volume.

Daix (France), New York City (New York, United States), October 6, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral small molecule therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the presentation of three abstracts at the upcoming AASLD The Liver Meeting® 2026, to be held from November 5-9, 2026, in Denver, Colorado.

Inventiva NASDAQ: IVA said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in patients with metabolic dysfunction-associated steatohepatitis, or MASH.

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday.

Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript

Inventiva NASDAQ: IVA said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth quarter of 2026, after the last patient completed the study's 72-week visit earlier this month.

Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Daix (France), New York City (New York, United States), August 31, 2026 –  Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Chris Benecchi as Chief Operating Officer. A proven biopharmaceutical leader with extensive experience in building organizations, preparing medicines for launch and integrating cross-functional operations, Mr. Benecchi will lead Inventiva's operational readiness as the Company approaches its pivotal NATiV3 Phase 3 topline study results of lanifibranor, in MASH, expected in Q4 2026, and prepares for potential commercialization.

Inventiva is positioned as a high-risk, clinical catalyst play targeting MASH with its oral pan-PPAR agonist, lanifibranor. Lanifibranor's potential lies in combination therapy, offering dual metabolic and anti-fibrotic benefits independent of weight loss, complementing GLP-1 and SGLT2 agents. Inventiva has secured sufficient liquidity through Q2 2027, with contingent access to further capital, and has strengthened governance ahead of the pivotal NATiV3 Phase 3 readout.